| human | Q5 |
| P106 | occupation | researcher | Q1650915 |
| Q50044397 | "Malignant" Left Ventricular Hypertrophy Identifies Subjects at High Risk for Progression to Asymptomatic Left Ventricular Dysfunction, Heart Failure, and Death: MESA (Multi-Ethnic Study of Atherosclerosis). |
| Q22241919 | 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines |
| Q59355889 | 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: Executive Summary |
| Q34318814 | 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines |
| Q44265041 | 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines |
| Q38072661 | 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration w |
| Q26779649 | 2015 ACC/AHA/SCAI Focused Update on Primary Percutaneous Coronary Intervention for Patients With ST-Elevation Myocardial Infarction: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention and the 2013 ACCF/AHA ... |
| Q34498935 | 2015 ACC/AHA/SCAI Focused Update on Primary Percutaneous Coronary Intervention for Patients With ST-Elevation Myocardial Infarction: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention and the 2013 ACCF/AHA Guideline |
| Q61667320 | 2015 ACC/AHA/SCAI focused update on primary percutaneous coronary intervention for patients with ST-elevation myocardial Infarction: An update of the 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention and the 2013 ACCF/AHA guideline |
| Q82450103 | A 4-tiered classification of left ventricular hypertrophy based on left ventricular geometry: the Dallas heart study |
| Q91438847 | A Proposal for Modest Revision of the Definition of Type 1 and Type 2 Myocardial Infarction |
| Q36641971 | A Prospective Analysis of Plasma Adiponectin and Risk of Incident Cancer: The Dallas Heart Study |
| Q29028464 | A Sensitive Cardiac Troponin T Assay in Stable Coronary Artery Disease |
| Q46090655 | A randomized controlled trial of a paclitaxel-eluting stent versus a similar bare-metal stent in saphenous vein graft lesions the SOS (Stenting of Saphenous Vein Grafts) trial |
| Q95476581 | A risk score for predicting coronary artery disease in women with angina pectoris and abnormal stress test finding |
| Q42043575 | A simple risk index for rapid initial triage of patients with ST-elevation myocardial infarction: an InTIME II substudy |
| Q46988582 | A tale of two trials: a comparison of the post-acute coronary syndrome lipid-lowering trials A to Z and PROVE IT-TIMI 22. |
| Q40716568 | Abciximab and early adjunctive percutaneous coronary intervention are associated with improved ST-segment resolution after thrombolysis: Observations from the TIMI 14 Trial |
| Q73382036 | Abciximab improves both epicardial flow and myocardial reperfusion in ST-elevation myocardial infarction. Observations from the TIMI 14 trial |
| Q86984475 | Accuracy of acute myocardial infarction clinical diagnosis and its implications |
| Q45905435 | Accuracy of estimating resting oxygen uptake and implications for hemodynamic assessment. |
| Q80998599 | Acute changes in circulating natriuretic peptide levels in relation to myocardial ischemia |
| Q37415740 | Acute decline in renal function, inflammation, and cardiovascular risk after an acute coronary syndrome |
| Q85968614 | Acute troponin elevation and the classification of myocardial infarction |
| Q36465527 | Addition of highly sensitive troponin T and N-terminal pro-B-type natriuretic peptide to electrocardiography for detection of left ventricular hypertrophy: results from the Dallas Heart Study |
| Q92013539 | Adherence to Guideline Medication Recommendations to Prevent Atherosclerotic Cardiovascular Disease Progression Among Adults With Prior Myocardial Infarction |
| Q49184401 | Adiponectin protects against incident hypertension independent of body fat distribution: observations from the Dallas Heart Study. |
| Q46020147 | Age Differences in Hospital Mortality for Acute Myocardial Infarction: Implications for Hospital Profiling. |
| Q37700011 | Age- and sex-dependent upper reference limits for the high-sensitivity cardiac troponin T assay. |
| Q95336954 | Aging and Diabetes: Shifting the Risk Trajectory With High-Sensitivity Cardiac Troponins |
| Q114612417 | American Heart Association Precision Medicine Platform Addresses Challenges in Data Sharing |
| Q37075402 | Amino-terminal pro-B-type natriuretic peptides in stable and unstable ischemic heart disease |
| Q91111429 | Amyloid-Beta (1-40) Peptide and Subclinical Cardiovascular Disease |
| Q37779239 | An evidence-based algorithm for the use of B-type natriuretic testing in acute coronary syndromes. |
| Q44507065 | Angiographic and clinical characteristics associated with the development of Q-wave and non-Q-wave myocardial infarction in the thrombolysis in myocardial infarction (TIMI) 14 trial |
| Q85404817 | Antinuclear Antibodies Are Associated With All-Cause Mortality and Cardiovascular Outcomes in the General Population |
| Q57300222 | Antinuclear antibodies in the general population: positive association with inflammatory and vascular biomarkers but not traditional cardiovascular risk factors |
| Q46983769 | Antiplatelet agents make a comeback in ST-elevation myocardial infarction |
| Q91764288 | Application of non-HDL cholesterol for population-based cardiovascular risk stratification: results from the Multinational Cardiovascular Risk Consortium |
| Q43812365 | Application of the TIMI risk score for ST-elevation MI in the National Registry of Myocardial Infarction 3. |
| Q39847754 | Application of the screening for Heart Attack Prevention and Education Task Force recommendations to an urban population: observations from the Dallas Heart Study |
| Q43541698 | Applying a Big Data Approach to Biomarker Discovery: Running Before We Walk? |
| Q92131024 | Arrhythmias and Adaptations of the Cardiac Conduction System in Former National Football League Players |
| Q50084363 | Ascending Aortic Dimensions in Former National Football League Athletes. |
| Q28194872 | Aspirin, clopidogrel, or both for secondary prevention of coronary disease |
| Q73181314 | Assessing the success of fibrinolysis: can we let the interventionalist rest? |
| Q92643169 | Assessment and Treatment of Patients With Type 2 Myocardial Infarction and Acute Nonischemic Myocardial Injury |
| Q84274776 | Assessment of adiponectin and the risk of recurrent cardiovascular events in patients presenting with an acute coronary syndrome: observations from the Pravastatin Or atorVastatin Evaluation and Infection Trial-Thrombolysis in Myocardial Infarction |
| Q84077703 | Assessment of cardiac structure and function in patients without and with peripheral oedema during rosiglitazone treatment |
| Q89423759 | Association Between Peptidoglycan Recognition Protein-1 and Incident Atherosclerotic Cardiovascular Disease Events: The Dallas Heart Study |
| Q52983596 | Association Between Sedentary Time and Coronary Artery Calcium. |
| Q42170189 | Association among plasma levels of monocyte chemoattractant protein-1, traditional cardiovascular risk factors, and subclinical atherosclerosis |
| Q42613896 | Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. |
| Q37495520 | Association between cardiorespiratory fitness and accelerometer-derived physical activity and sedentary time in the general population |
| Q37235902 | Association between circulating soluble receptor for advanced glycation end products and atherosclerosis: observations from the Dallas Heart Study. |
| Q41059867 | Association between low ankle-brachial index and accelerometer-derived sedentary and exercise time in the asymptomatic general population |
| Q44103066 | Association between natriuretic peptides and mortality among patients admitted with myocardial infarction: a report from the ACTION Registry(R)-GWTG™. |
| Q90854859 | Association between neighborhood-level socioeconomic deprivation and incident hypertension: A longitudinal analysis of data from the Dallas heart study |
| Q36787512 | Association between number of live births and markers of subclinical atherosclerosis: The Dallas Heart Study |
| Q44310088 | Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes |
| Q48835844 | Association between renal function and circulating levels of natriuretic peptides (from the Dallas Heart Study). |
| Q39138585 | Association of 30-Day Readmission Metric for Heart Failure Under the Hospital Readmissions Reduction Program With Quality of Care and Outcomes |
| Q102055657 | Association of Baseline Low-Density Lipoprotein Cholesterol and Percentage Low-Density Lipoprotein Cholesterol Reduction With Statins, Ezetimibe, and PCSK9 Inhibition |
| Q102131442 | Association of Body Mass Index and Age With Morbidity and Mortality in Patients Hospitalized With COVID-19: Results From the American Heart Association COVID-19 Cardiovascular Disease Registry |
| Q90633355 | Association of Cardiac Injury and Malignant Left Ventricular Hypertrophy With Risk of Heart Failure in African Americans: The Jackson Heart Study |
| Q101220339 | Association of Circulating Monocyte Chemoattractant Protein-1 Levels With Cardiovascular Mortality: A Meta-analysis of Population-Based Studies |
| Q38372737 | Association of Concentric Left Ventricular Hypertrophy With Subsequent Change in Left Ventricular End-Diastolic Volume: The Dallas Heart Study |
| Q92513012 | Association of Galectin-3 With Diabetes Mellitus in the Dallas Heart Study |
| Q102055638 | Association of Genetic West African Ancestry, Blood Pressure Response to Therapy, and Cardiovascular Risk Among Self-Reported Black Individuals in the Systolic Blood Pressure Reduction Intervention Trial (SPRINT) |
| Q88034848 | Association of Hospital Performance Based on 30-Day Risk-Standardized Mortality Rate With Long-term Survival After Heart Failure Hospitalization: An Analysis of the Get With The Guidelines-Heart Failure Registry |
| Q61634424 | Association of Lipoprotein-Associated Phospholipase A2 Mass and Activity with Coronary and Aortic Atherosclerosis: Findings from the Dallas Heart Study |
| Q89413772 | Association of Out-of-Pocket Annual Health Expenditures With Financial Hardship in Low-Income Adults With Atherosclerotic Cardiovascular Disease in the United States |
| Q41177392 | Association of Patient Enrollment in Medicare Part D With Outcomes After Acute Myocardial Infarction |
| Q36356524 | Association of US Centers for Medicare and Medicaid Services Hospital 30-Day Risk-Standardized Readmission Metric With Care Quality and Outcomes After Acute Myocardial Infarction: Findings From the National Cardiovascular Data Registry/Acute Coronar |
| Q36074394 | Association of a 4-Tiered Classification of LV Hypertrophy With Adverse CV Outcomes in the General Population. |
| Q93147795 | Association of a Novel Protocol for Rapid Exclusion of Myocardial Infarction With Resource Use in a US Safety Net Hospital |
| Q44829209 | Association of a pulsatile blood flow pattern on coronary arteriography and short-term clinical outcomes in acute myocardial infarction |
| Q47222907 | Association of acute kidney injury and chronic kidney disease with processes of care and long-term outcomes in patients with acute myocardial infarction |
| Q90827612 | Association of acute myocardial infarction cardiac arrest patient volume and in-hospital mortality in the United States: Insights from the National Cardiovascular Data Registry Acute Coronary Treatment And Intervention Outcomes Network Registry |
| Q46255547 | Association of cardiac troponin I with disease severity and outcomes in patients with pulmonary hypertension |
| Q35634804 | Association of cardiorespiratory fitness with left ventricular remodeling and diastolic function: the Cooper Center Longitudinal Study |
| Q45035244 | Association of chronic lung disease with treatments and outcomes patients with acute myocardial infarction |
| Q43266267 | Association of cystatin C with left ventricular structure and function: the Dallas Heart Study. |
| Q45052091 | Association of elevated B-type natriuretic peptide levels with angiographic findings among patients with unstable angina and non-ST-segment elevation myocardial infarction |
| Q37588805 | Association of growth differentiation factor-15 with coronary atherosclerosis and mortality in a young, multiethnic population: observations from the Dallas Heart Study |
| Q31120331 | Association of hospital myocardial infarction volume with adherence to American College of Cardiology/American Heart Association performance measures: Insights from the National Cardiovascular Data Registry |
| Q40158328 | Association of prediabetes by fasting glucose and/or haemoglobin A1c levels with subclinical atherosclerosis and impaired renal function: observations from the Dallas Heart Study |
| Q36574151 | Association of serial measures of cardiac troponin T using a sensitive assay with incident heart failure and cardiovascular mortality in older adults. |
| Q64086134 | Association of the New Peer Group-Stratified Method With the Reclassification of Penalty Status in the Hospital Readmission Reduction Program |
| Q41666469 | Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population |
| Q53153245 | Association of troponin T, detected with highly sensitive assay, and outcomes in infective endocarditis. |
| Q48317367 | Associations among androgens, estrogens, and natriuretic peptides in young women: observations from the Dallas Heart Study |
| Q46658441 | Associations between soluble CD40 ligand, atherosclerosis risk factors, and subclinical atherosclerosis: results from the Dallas Heart Study |
| Q34163322 | Associations of four circulating chemokines with multiple atherosclerosis phenotypes in a large population-based sample: results from the dallas heart study |
| Q37117087 | Associations of visceral and abdominal subcutaneous adipose tissue with markers of cardiac and metabolic risk in obese adults |
| Q57796499 | Astronaut Cardiovascular Health and Risk Modification (Astro-CHARM) Coronary Calcium Atherosclerotic Cardiovascular Disease Risk Calculator |
| Q34207126 | Atherosclerotic cardiovascular disease prevention: a comparison between the third adult treatment panel and the new 2013 Treatment of Blood Cholesterol Guidelines. |
| Q43124911 | B-type natriuretic peptide and the effect of ranolazine in patients with non-ST-segment elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST Elevation Acute Corona |
| Q80356150 | B-type natriuretic peptide at presentation and prognosis in patients with ST-segment elevation myocardial infarction: an ENTIRE-TIMI-23 substudy |
| Q48237778 | B-type natriuretic peptide in cardiovascular disease |
| Q35152072 | B-type natriuretic peptide in ischemic heart disease |
| Q79837581 | Benchmarks for the assessment of novel cardiovascular biomarkers |
| Q36619158 | Biomarkers in cardiovascular disease: integrating pathophysiology into clinical practice |
| Q43541434 | Biomarkers in clinical trials: can we move from fortune telling to disease profiling? |
| Q36541403 | Biomarkers of chronic cardiac injury and hemodynamic stress identify a malignant phenotype of left ventricular hypertrophy in the general population |
| Q36921225 | Body Size Misperception: A Novel Determinant in the Obesity Epidemic |
| Q36960562 | Body fat distribution and incident cardiovascular disease in obese adults |
| Q58845737 | Brain natriuretic peptide and left ventricular dysfunction in chagasic cardiomyopathy |
| Q48924555 | Brain natriuretic peptide measurement in Chagas heart disease: marker of ventricular dysfunction and arrhythmia. |
| Q48434740 | Brain natriuretic peptide measurement in acute coronary syndromes: ready for clinical application? |
| Q47615659 | Burden of Catastrophic Health Expenditures for Acute Myocardial Infarction and Stroke Among Uninsured in the United States |
| Q40258690 | Can biomarkers improve prediction of future cardiovascular events in patients with cardiovascular disease? |
| Q84715266 | Capturing the pathophysiology of acute coronary syndromes with circulating biomarkers |
| Q48086080 | Cardiac Troponins and the Future of Precision Medicine |
| Q33926203 | Cardiac troponin I for stratification of early outcomes and the efficacy of enoxaparin in unstable angina: a TIMI-11B substudy |
| Q34768805 | Cardiac troponin T measured by a highly sensitive assay predicts coronary heart disease, heart failure, and mortality in the Atherosclerosis Risk in Communities Study |
| Q37556336 | Cardiorespiratory Fitness and Highly Sensitive Cardiac Troponin Levels in a Preventive Medicine Cohort |
| Q37588795 | Cardiorespiratory fitness and classification of risk of cardiovascular disease mortality |
| Q99709908 | Cardiovascular Biomarkers and Imaging in Older Adults: JACC Council Perspectives |
| Q26853015 | Cardiovascular care facts: a report from the national cardiovascular data registry: 2011 |
| Q35115038 | Cardiovascular lifetime risk predicts incidence of coronary calcification in individuals with low short-term risk: the Dallas Heart Study |
| Q82723113 | Cardiovascular risk indicators and perceived race/ethnic discrimination in the Dallas Heart Study |
| Q40059212 | Care Transitions After Acute Myocardial Infarction for Transferred-In Versus Direct-Arrival Patients |
| Q37495523 | Changes in mid-life fitness predicts heart failure risk at a later age independent of interval development of cardiac and noncardiac risk factors: the Cooper Center Longitudinal Study |
| Q46587879 | Changes in right ventricular structure and function assessed using cardiac magnetic resonance imaging in bosentan-treated patients with pulmonary arterial hypertension. |
| Q30725922 | Characteristics, management, and outcomes of cocaine-positive patients with acute coronary syndrome (from the National Cardiovascular Data Registry). |
| Q90040184 | Characterization and Trajectory of Coronary Artery Calcium Percentiles: The Dallas Heart Study |
| Q36631770 | Churches as targets for cardiovascular disease prevention: comparison of genes, nutrition, exercise, wellness and spiritual growth (GoodNEWS) and Dallas County populations |
| Q93059472 | Circulating Monocyte Chemoattractant Protein-1 and Risk of Stroke: Meta-Analysis of Population-Based Studies Involving 17 180 Individuals |
| Q36469686 | Circulating levels of matrix metalloproteinase-9 and abdominal aortic pathology: from the Dallas Heart Study |
| Q84517994 | Circulating lymphotoxin β receptor and atherosclerosis: observations from the Dallas Heart Study |
| Q41165846 | Circulating microRNAs: Potential Markers of Cardiotoxicity in Children and Young Adults Treated With Anthracycline Chemotherapy |
| Q89936071 | Clinical Relevance of the 99th Percentile Upper Reference Limit for High-Sensitivity Cardiac Troponin Assays |
| Q80838278 | Clinical application of C-reactive protein across the spectrum of acute coronary syndromes |
| Q83200588 | Clinical characteristics, vascular function, and inflammation in women with angina in the absence of coronary atherosclerosis: the Dallas Heart Study |
| Q73663532 | Clinical efficacy of three assays for cardiac troponin I for risk stratification in acute coronary syndromes: a Thrombolysis In Myocardial Infarction (TIMI) 11B Substudy |
| Q54283406 | Clinical presentation and angiographic characteristics of saphenous vein graft failure after stenting: insights from the SOS (stenting of saphenous vein grafts) trial. |
| Q79922447 | Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial |
| Q30844989 | Clinical trial participation after myocardial infarction in a national cardiovascular data registry |
| Q92533316 | Closing the Book on Androgens and Natriuretic Peptides |
| Q73173168 | Combination reperfusion therapy with abciximab and reduced dose reteplase: results from TIMI 14. The Thrombolysis in Myocardial Infarction (TIMI) 14 Investigators |
| Q73947470 | Combination therapy with abciximab reduces angiographically evident thrombus in acute myocardial infarction: a TIMI 14 substudy |
| Q97651578 | Combining Biomarkers and Imaging for Short-Term Assessment of Cardiovascular Disease Risk in Apparently Healthy Adults |
| Q47773642 | Comparison of B-type natriuretic peptide levels in patients with heart failure with versus without mitral regurgitation |
| Q47967788 | Comparison of Readmission Rates After Acute Myocardial Infarction in 3 Patient Age Groups (18 to 44, 45 to 64, and ≥65 Years) in the United States. |
| Q73222169 | Comparison of a 60- versus 90-minute determination of ST-segment resolution after thrombolytic therapy for acute myocardial infarction. In TIME-II Investigators. Intravenous nPA for Treatment of Infarcting Myocardium Early-II |
| Q39766012 | Comparison of performance on Hospital Compare process measures and patient outcomes between hospitals that do and do not participate in Acute Coronary Treatment and Intervention Outcomes Network Registry-Get With The Guidelines |
| Q88333588 | Conceptual Framework for Addressing Residual Atherosclerotic Cardiovascular Disease Risk in the Era of Precision Medicine |
| Q33691730 | Concurrent evaluation of novel cardiac biomarkers in acute coronary syndrome: myeloperoxidase and soluble CD40 ligand and the risk of recurrent ischaemic events in TACTICS-TIMI 18. |
| Q47844132 | Contemporary Epidemiology of Heart Failure in Fee-For-Service Medicare Beneficiaries Across Healthcare Settings. |
| Q30842297 | Contemporary patterns of discharge aspirin dosing after acute myocardial infarction in the United States: results from the National Cardiovascular Data Registry (NCDR). |
| Q46084017 | Contemporary use of embolic protection devices in saphenous vein graft interventions: Insights from the stenting of saphenous vein grafts trial |
| Q48905382 | Continued benefit from paclitaxel-eluting compared with bare-metal stent implantation in saphenous vein graft lesions during long-term follow-up of the SOS (Stenting of Saphenous Vein Grafts) trial. |
| Q36081956 | Continuous Dose-Response Association Between Sedentary Time and Risk for Cardiovascular Disease: A Meta-analysis. |
| Q59608183 | Contributors |
| Q41206488 | Coronary Artery Calcium Improves Risk Classification in Younger Populations |
| Q53062134 | Coronary artery calcification and family history of myocardial infarction in the Dallas heart study. |
| Q91418443 | Cost-Related Medication Nonadherence in Adults With Atherosclerotic Cardiovascular Disease in the United States, 2013 to 2017 |
| Q36527845 | Current status of risk stratification methods in acute coronary syndromes |
| Q38667631 | Defining coronary artery calcium concordance and repeatability - Implications for development and change: The Dallas Heart Study. |
| Q37291489 | Detection of acute changes in circulating troponin in the setting of transient stress test-induced myocardial ischaemia using an ultrasensitive assay: results from TIMI 35. |
| Q39650799 | Determinants of Racial/Ethnic Differences in Cardiorespiratory Fitness (from the Dallas Heart Study). |
| Q74313112 | Determinants of improvement in epicardial flow and myocardial perfusion for ST elevation myocardial infarction; insights from TIMI 14 and InTIME-II |
| Q30576479 | Diabetes mellitus and trends in hospital survival after myocardial infarction, 1994 to 2006: data from the national registry of myocardial infarction |
| Q90666978 | Diagnostic Thresholds for Blood Pressure Measured at Home in the Context of the 2017 Hypertension Guideline |
| Q36516029 | Diagnostic and prognostic utility of brain natriuretic Peptide in subjects admitted to the ICU with hypoxic respiratory failure due to noncardiogenic and cardiogenic pulmonary edema |
| Q37407759 | Differential associations between soluble cellular adhesion molecules and atherosclerosis in the Dallas Heart Study: a distinct role for soluble endothelial cell-selective adhesion molecule |
| Q43646110 | Discordant effects of rosiglitazone on novel inflammatory biomarkers |
| Q36444407 | Disparities in counseling for lifestyle modification among obese adults: insights from the Dallas Heart Study |
| Q38133318 | Do established biomarkers such as B-type natriuretic peptide and troponin predict rejection? |
| Q22306341 | Dose–Response Relationship Between Physical Activity and Risk of Heart FailureCLINICAL PERSPECTIVE |
| Q41627374 | Dynamic Relation of Changes in Weight and Indices of Fat Distribution With Cardiac Structure and Function: The Dallas Heart Study. |
| Q36566370 | Dysfunctional adiposity and the risk of prediabetes and type 2 diabetes in obese adults |
| Q33710731 | ED administration of thienopyridines in non-ST-segment elevation myocardial infarction: results from the NCDR |
| Q123289895 | EFFECT OF EXTENDED-RELEASE NIACIN ON REACTIVE HYPEREMIA PERIPHERAL ARTERIAL TONOMETRY AND ENDOTHELIAL PROGENITOR CELL MOBILIZATION: INSIGHTS FROM THE ATHEROSCLEROSIS LESION PROGRESSION INTERVENTION USING NIACIN EXTENDED RELEASE IN SAPHENOUS VEIN GRA |
| Q92533574 | Early Repolarization Pattern Is Associated With Increased Left Ventricular Mass: Insights From the Dallas Heart Study |
| Q34550538 | Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial |
| Q74484756 | Early noninvasive detection of failed epicardial reperfusion after fibrinolytic therapy |
| Q61634168 | Effect of Concomitant Use of Clopidogrel and Proton Pump Inhibitors After Percutaneous Coronary Intervention |
| Q100547187 | Effect of Doxorubicin on Myocardial Bicarbonate Production from Pyruvate Dehydrogenase in Women with Breast Cancer |
| Q91316010 | Effect of Exercise and Pharmacological Interventions on Visceral Adiposity: A Systematic Review and Meta-analysis of Long-term Randomized Controlled Trials |
| Q61633930 | Effect of Extended-Release Niacin on Carotid Intima Media Thickness, Reactive Hyperemia, and Endothelial Progenitor Cell Mobilization: Insights From the Atherosclerosis Lesion Progression Intervention Using Niacin Extended Release in Saphenous Vein G |
| Q61633945 | Effect of Extended-Release Niacin on Saphenous Vein Graft Atherosclerosis: Insights from the Atherosclerosis Lesion Progression Intervention Using Niacin Extended Release in Saphenous Vein Grafts (ALPINE-SVG) Pilot Trial |
| Q26783958 | Effect of Mineralocorticoid Receptor Antagonists on Cardiac Structure and Function in Patients With Diastolic Dysfunction and Heart Failure With Preserved Ejection Fraction: A Meta-Analysis and Systematic Review |
| Q46973471 | Effect of glucose-insulin-potassium (GIK) infusion on biomarkers of cardiovascular risk in ST elevation myocardial infarction (STEMI): insight into the failure of GIK. |
| Q45148891 | Effect of glucose-insulin-potassium infusion on plasma free fatty acid concentrations in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction |
| Q46989794 | Effect of intensive lipid-lowering therapy on mortality after acute coronary syndrome (a patient-level analysis of the Aggrastat to Zocor and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 trial |
| Q86969573 | Effect of treatment with rosiglitazone on high-sensitivity cardiac troponin levels among patients with type 2 diabetes mellitus |
| Q36877682 | Effectiveness and Safety of Aldosterone Antagonist Therapy Use Among Older Patients With Reduced Ejection Fraction After Acute Myocardial Infarction |
| Q44130291 | Effects of early treatment with statins on short-term clinical outcomes in acute coronary syndromes: a meta-analysis of randomized controlled trials |
| Q60918730 | Effects of gender in resident evaluations and certifying examination pass rates |
| Q35828309 | Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overview |
| Q35907250 | Electrocardiographic patterns of proximal left anterior descending artery occlusion in ST-elevation myocardial infarction may be modified by 3-vessel coronary artery disease |
| Q28213887 | Enoxaparin versus unfractionated heparin in patients treated with tirofiban, aspirin and an early conservative initial management strategy: results from the A phase of the A-to-Z trial |
| Q51889750 | Estimated glomerular filtration rate, inflammation, and cardiovascular events after an acute coronary syndrome. |
| Q48329269 | Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18. |
| Q58094147 | Evaluation of a Novel Rule-Out Myocardial Infarction Protocol Incorporating High-Sensitivity Troponin T in a US Hospital |
| Q34449604 | Evaluation of coronary artery calcium screening strategies focused on risk categories: the Dallas Heart Study |
| Q34241396 | Evaluation of multiple biomarkers of cardiovascular stress for risk prediction and guiding medical therapy in patients with stable coronary disease |
| Q44526001 | Evaluation of the AccuTnI cardiac troponin I assay for risk assessment in acute coronary syndromes |
| Q28200409 | Evaluation of the National Cholesterol Education Program Adult Treatment Panel III algorithm for selecting candidates for statin therapy: insights from the A to Z trial |
| Q79160423 | Evaluation of the association of proximal coronary culprit artery lesion location with clinical outcomes in acute myocardial infarction |
| Q36108792 | Evolving considerations in the management of patients with left bundle branch block and suspected myocardial infarction |
| Q31151437 | Executive Summary: Trends in U.S. Cardiovascular Care: 2016 Report From 4 ACC National Cardiovascular Data Registries |
| Q38983114 | Factors Associated With Left Atrial Remodeling in the General Population |
| Q38777189 | Factors Associated With and Prognostic Implications of Cardiac Troponin Elevation in Decompensated Heart Failure With Preserved Ejection Fraction: Findings From the American Heart Association Get With The Guidelines-Heart Failure Program |
| Q98943678 | Fibrinolytic Strategy for ST-Segment-Elevation Myocardial Infarction: A Contemporary Review in Context of the COVID-19 Pandemic |
| Q89228084 | Finding an effective treatment for microvascular obstruction in STEMI: a road to perdition? |
| Q40296294 | Fitness in Young Adulthood and Long-Term Cardiac Structure and Function: The CARDIA Study |
| Q57486604 | Fourth universal definition of myocardial infarction (2018) |
| Q53355008 | Fracture and embolization of an inferior vena cava filter strut leading to cardiac tamponade. |
| Q81879842 | Free wall rupture in the elderly: deleterious effect of fibrinolytic therapy on the ageing heart |
| Q91281869 | Getting to an ImprOved Understanding of Low-Density Lipoprotein-Cholesterol and Dyslipidemia Management (GOULD): Methods and baseline data of a registry of high cardiovascular risk patients in the United States |
| Q42785403 | Glycated hemoglobin in 14,850 adolescent blood donors: a pilot screening program |
| Q35021594 | HDL cholesterol efflux capacity and incident cardiovascular events |
| Q73943185 | Heart-type fatty acid binding protein as a marker of reperfusion after thrombolytic therapy |
| Q33380858 | Hemodynamics and epoprostenol use are associated with thrombocytopenia in pulmonary arterial hypertension |
| Q40280421 | High prevalence of elevated haemoglobin A1C among adolescent blood donors: Results from a voluntary screening programme including 31,546 adolescents |
| Q40350551 | High-Sensitive Cardiac Troponin T as an Early Biochemical Signature for Clinical and Subclinical Heart Failure: MESA (Multi-Ethnic Study of Atherosclerosis). |
| Q91573862 | High-Sensitivity Troponin I and Incident Coronary Events, Stroke, Heart Failure Hospitalization, and Mortality in the ARIC Study |
| Q51741610 | High-sensitivity cardiac troponin I assay to screen for acute rejection in patients with heart transplant. |
| Q34718054 | High-sensitivity troponin T and cardiovascular events in systolic blood pressure categories: atherosclerosis risk in communities study |
| Q37378648 | Higher natriuretic peptide levels associate with a favorable adipose tissue distribution profile |
| Q83798233 | Highly sensitive troponin assays and the cardiology community: a love/hate relationship? |
| Q43725882 | Homoarginine and cardiovascular outcome in the population-based Dallas Heart Study |
| Q61997166 | INTERACTIONS BETWEEN SMOKING, CIRCULATING PULMONARY SURFACTANT PROTEIN-B AND AORTIC ATHEROSCLEROSIS IN THE DALLAS HEART STUDY |
| Q44035536 | Identification of patients at high risk for death and cardiac ischemic events after hospital discharge |
| Q41410075 | Impact of Chronic Total Occlusions and Coronary Revascularization on All-Cause Mortality and the Incidence of Ventricular Arrhythmias in Patients With Ischemic Cardiomyopathy. |
| Q39213764 | Impact of Smoking on Circulating Cardiac Troponin I Concentrations and Cardiovascular Events in the General Population: The HUNT Study (Nord-Trøndelag Health Study). |
| Q48745221 | Impact of body mass and body composition on circulating levels of natriuretic peptides: results from the Dallas Heart Study |
| Q34095167 | Impact of body weight and extreme obesity on the presentation, treatment, and in-hospital outcomes of 50,149 patients with ST-Segment elevation myocardial infarction results from the NCDR (National Cardiovascular Data Registry). |
| Q30988733 | Impact of contrast agent type (ionic versus nonionic) used for coronary angiography on angiographic, electrocardiographic, and clinical outcomes following thrombolytic administration in acute myocardial infarction |
| Q46047402 | Impact of diabetes mellitus on epicardial and microvascular flow after fibrinolytic therapy |
| Q39421978 | Impact of moderate physical activity on the longitudinal trajectory of a cardiac specific biomarker of injury: Results from a randomized pilot study of exercise intervention |
| Q86772177 | Impact of sex on the prognostic value of high-sensitivity cardiac troponin I in the general population: the HUNT study |
| Q100696226 | Implantable Cardioverter Defibrillator Utilization and Mortality Among Patients ≥ 65 Years of Age with a Low Ejection Fraction Following Coronary Revascularization |
| Q40807600 | Implantable Cardioverter-Defibrillator Use Among Medicare Patients With Low Ejection Fraction After Acute Myocardial Infarction |
| Q80843452 | Implications of family history of myocardial infarction in young women |
| Q86058781 | Inaccuracy of estimated resting oxygen uptake in the clinical setting |
| Q91213376 | Incorporation of Biomarkers Into Risk Assessment for Allocation of Antihypertensive Medication According to the 2017 ACC/AHA High Blood Pressure Guideline: A Pooled Cohort Analysis |
| Q28196838 | Increased cardiovascular risk associated with diabetes in Dallas County |
| Q33763313 | Increases in myocardial workload induced by rapid atrial pacing trigger alterations in global metabolism. |
| Q53411676 | Independent associations between metabolic syndrome, diabetes mellitus and atherosclerosis: observations from the Dallas Heart Study. |
| Q28194144 | Infarct-related coronary artery patency and medication use prior to ST-segment elevation myocardial infarction |
| Q74588031 | Infective endocarditis |
| Q36808689 | Influence of race and sex on lipoprotein-associated phospholipase A2 levels: observations from the Dallas Heart Study. |
| Q39223745 | Intensive Care Unit Utilization and Mortality Among Medicare Patients Hospitalized With Non-ST-Segment Elevation Myocardial Infarction |
| Q89190995 | Intensive Care Utilization in Stable Patients With ST-Segment Elevation Myocardial Infarction Treated With Rapid Reperfusion |
| Q28244928 | Interactions between smoking, pulmonary surfactant protein B, and atherosclerosis in the general population: the Dallas Heart Study |
| Q43845252 | Interleukin-18, the metabolic syndrome, and subclinical atherosclerosis: results from the Dallas Heart Study. |
| Q58587825 | Intraosseous versus Intravenous access in Patients with Out-of-Hospital Cardiac Arrest: Insights from the Resuscitation Outcomes Consortium Continuous Chest Compression Trial |
| Q86097255 | Is subclinical myocardial injury the smoking gun linking obesity with heart failure? |
| Q43229364 | Keeping our eyes on the prize: low density lipoprotein cholesterol |
| Q85669339 | Keeping the genie in the bottle: growth hormone and cardiovascular disease |
| Q113861084 | Kidney Function Specific Reference Limits for N-terminal Pro Brain Natriuretic Peptide and High Sensitivity Troponin T: The Systolic Blood Pressure Intervention Trial |
| Q36547084 | Left atrial structure and function and clinical outcomes in the general population. |
| Q78692684 | Left hemiparesis from atrial myxoma emboli |
| Q84392184 | Left ventricular hypertrophy, aortic wall thickness, and lifetime predicted risk of cardiovascular disease:the Dallas Heart Study |
| Q80087773 | Left ventricular hypertrophy, subclinical atherosclerosis, and inflammation |
| Q45286444 | Lessons from the heart: troponin elevations in patients with established peripheral artery disease |
| Q46155332 | Letter by Neeland and de Lemos regarding article, "Rates of cardiac catheterization cancelation for ST-segment elevation myocardial infarction after activation by emergency medical services or emergency physicians: results from the North Carolina Ca |
| Q36716944 | Lifetime risks for cardiovascular disease mortality by cardiorespiratory fitness levels measured at ages 45, 55, and 65 years in men. The Cooper Center Longitudinal Study |
| Q87447206 | Limitations of using cardiac catheterization rates to assess the quality of care for patients with non-ST-segment elevation myocardial infarction |
| Q90669114 | Long-Term Association of Low-Density Lipoprotein Cholesterol With Cardiovascular Mortality in Individuals at Low 10-Year Risk of Atherosclerotic Cardiovascular Disease |
| Q92264930 | Longitudinal trajectories of hospital performance across targeted cardiovascular conditions in the USA |
| Q98390860 | Lot-to-Lot Variation for Commercial High-Sensitivity Cardiac Troponin: Can We Realistically Report Down to the Assay's Limit of Detection? |
| Q83333573 | Low levels of circulating troponin as an intermediate phenotype in the pathway to heart failure |
| Q80020271 | Low voltage on the electrocardiogram is a marker of disease severity and a risk factor for adverse outcomes in patients with heart failure due to systolic dysfunction |
| Q22241914 | Management of Cocaine-Associated Chest Pain and Myocardial Infarction: A Scientific Statement From the American Heart Association Acute Cardiac Care Committee of the Council on Clinical Cardiology |
| Q85936777 | Measures of adiposity and fat distribution and risk of diabetes--reply |
| Q39657374 | Methodologic and clinical validation of the TIMI myocardial perfusion grade in acute myocardial infarction |
| Q85906656 | Mild hyponatremia is associated with an increased risk of death in an ambulatory setting |
| Q78489495 | Minimal ST-segment deviation: a simple, noninvasive method for identifying patients with a patent infarction-related artery after fibrinolytic administration |
| Q31009068 | Modest Associations Between Electronic Health Record Use and Acute Myocardial Infarction Quality of Care and Outcomes: Results From the National Cardiovascular Data Registry |
| Q48630098 | Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide |
| Q40266203 | Multimodality Strategy for Cardiovascular Risk Assessment: Performance in 2 Population-Based Cohorts |
| Q57413965 | Multiple Biomarker Panels for Cardiovascular Risk Assessment |
| Q30426457 | Myocardial ischemia induced by rapid atrial pacing causes troponin T release detectable by a highly sensitive assay: insights from a coronary sinus sampling study |
| Q43657639 | Myoglobin levels at 12 hours identify patients at low risk for 30-day mortality after thrombolysis in acute myocardial infarction: a Thrombolysis in Myocardial Infarction 10B substudy |
| Q35566147 | Natriuretic peptide hormone measurement in acute coronary syndromes |
| Q31126960 | Natriuretic peptides and integrated risk assessment for cardiovascular disease: an individual-participant-data meta-analysis |
| Q37779236 | Natriuretic peptides in the prognosis and management of acute coronary syndromes |
| Q88922936 | Neighborhood Socioeconomic Disadvantage and Care After Myocardial Infarction in the National Cardiovascular Data Registry |
| Q79086074 | Nesiritide in acute heart failure |
| Q51809043 | Newer biomarkers in heart failure. |
| Q61634184 | No free lunches: balancing bleeding and efficacy with ticagrelor |
| Q31043584 | Non-eligibility for reperfusion therapy in patients presenting with ST-segment elevation myocardial infarction: Contemporary insights from the National Cardiovascular Data Registry (NCDR). |
| Q44642199 | Noninvasive assessment of reperfusion therapy: slow progress towards a worthwhile goal |
| Q35690501 | Older Adults, "Malignant" Left Ventricular Hypertrophy, and Associated Cardiac-Specific Biomarker Phenotypes to Identify the Differential Risk of New-Onset Reduced Versus Preserved Ejection Fraction Heart Failure: CHS (Cardiovascular Health Study). |
| Q39133814 | On-treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT). |
| Q46415506 | Outcomes of patients with acute coronary syndrome and previous coronary artery bypass grafting (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy [PROVE IT-TIMI 22] and the Aggrastat to Zocor [A to Z] trials). |
| Q86547156 | Overriding concerns: the role of electronic medical record-based best practice alerts in reducing unnecessary laboratory testing |
| Q48788154 | Paclitaxel-eluting stents reduce neointimal hyperplasia compared to bare metal stents in saphenous vein grafts: intravascular ultrasonography analysis of the SOS (Stenting of Saphenous Vein Grafts) trial. |
| Q53276113 | Paclitaxel-eluting vs. bare metal stent implantation in saphenous vein graft lesions: Very long-term follow-up of the SOS (Stenting of Saphenous vein grafts) trial. |
| Q35837838 | Pathophysiology, prognostic significance and clinical utility of B-type natriuretic peptide in acute coronary syndromes |
| Q35634810 | Perceived lifetime risk for cardiovascular disease (from the Dallas Heart Study). |
| Q101059075 | Performance of the Pooled Cohort Equations to Estimate Atherosclerotic Cardiovascular Disease Risk by Body Mass Index |
| Q36665888 | Physical activity, change in biomarkers of myocardial stress and injury, and subsequent heart failure risk in older adults |
| Q90667569 | Physician-Specific Practice Patterns About Discharge Readiness and Heart Failure Utilization Outcomes |
| Q40753513 | Plasma concentration of soluble vascular cell adhesion molecule-1 and subsequent cardiovascular risk |
| Q98390812 | Plasma dehydroepiandrosterone sulfate and cardiovascular disease risk in older men and women |
| Q51754844 | Plasma osteoprotegerin levels in the general population: relation to indices of left ventricular structure and function. |
| Q82277911 | Polycystic ovarian syndrome and subclinical atherosclerosis among women of reproductive age in the Dallas heart study |
| Q39985964 | Post-Hospital Outcomes of Patients With Acute Myocardial Infarction With Cardiogenic Shock: Findings From the NCDR. |
| Q39166191 | Prediction of 30-year risk for cardiovascular mortality by fitness and risk factor levels: the Cooper Center Longitudinal Study |
| Q46198445 | Predictors of reperfusion delay in patients with ST elevation myocardial infarction self-transported to the hospital (from the American Heart Association's Mission: Lifeline Program). |
| Q40153967 | Premature Clopidogrel Discontinuation After Drug-Eluting Stent Placement in a Large Urban Safety-Net Hospital. |
| Q83161925 | Prevalence and determinants of troponin T elevation in the general population |
| Q44764999 | Prevalence and outcomes of intermediate saphenous vein graft lesions: findings from the stenting of saphenous vein grafts randomized-controlled trial. |
| Q46445191 | Primary systemic amyloidosis presenting with advanced heart failure |
| Q41179292 | Prognostic Significance of High-Sensitivity Cardiac Troponin T Concentrations between the Limit of Blank and Limit of Detection in Community-Dwelling Adults: A Metaanalysis |
| Q48458047 | Prognostic utility of heart-type fatty acid binding protein in patients with acute coronary syndromes |
| Q77616462 | Prognostic value of N-terminal pro-atrial and pro-brain natriuretic peptide in patients with acute coronary syndromes |
| Q48161023 | Prognostic value of cardiac troponin I measured with a highly sensitive assay in patients with stable coronary artery disease |
| Q38410603 | Prognostic value of serial B-type natriuretic peptide testing during follow-up of patients with unstable coronary artery disease |
| Q46181202 | Race and gender differences in C-reactive protein levels |
| Q35581112 | Race-specific associations of myeloperoxidase with atherosclerosis in a population-based sample: the Dallas Heart Study |
| Q90080734 | Racial Differences in Cardiovascular Biomarkers in the General Population |
| Q92603784 | Racial Differences in Malignant Left Ventricular Hypertrophy and Incidence of Heart Failure: A Multicohort Study |
| Q35842030 | Racial Differences in Natriuretic Peptide Levels: The Dallas Heart Study. |
| Q102131453 | Racial and Ethnic Differences in Presentation and Outcomes for Patients Hospitalized with COVID-19: Findings from the American Heart Association's COVID-19 Cardiovascular Disease Registry |
| Q34123775 | Randomized comparison of the effects of rosiglitazone vs. placebo on peak integrated cardiovascular performance, cardiac structure, and function |
| Q87554370 | Rates of aldosterone antagonist use after myocardial infarction remain poor over time among guideline eligible patients |
| Q40459744 | Reassessment of Cardiac Function and Implantable Cardioverter-Defibrillator Use Among Medicare Patients With Low Ejection Fraction After Myocardial Infarction. |
| Q49644799 | Recognized Outstanding Reviewers for Circulation in 2017. |
| Q92005409 | Recognized Outstanding Reviewers for Circulation in 2019 |
| Q102070450 | Recognized Outstanding Reviewers for Circulation in 2020 |
| Q48857271 | Recurrent cardiovascular events with paclitaxel-eluting versus bare-metal stents in saphenous vein graft lesions: insights from the SOS (Stenting of Saphenous Vein Grafts) trial |
| Q40644185 | Regional Fat Distribution and Blood Pressure Level and Variability: The Dallas Heart Study |
| Q36535122 | Relation of Adiponectin to All-Cause Mortality, Cardiovascular Mortality, and Major Adverse Cardiovascular Events (from the Dallas Heart Study). |
| Q48715220 | Relation of coronary atherosclerosis determined by electron beam computed tomography and plasma levels of n-terminal pro-brain natriuretic peptide in a multiethnic population-based sample (the Dallas Heart Study). |
| Q45222649 | Relation of family history of myocardial infarction and the presence of coronary arterial calcium in various age and risk factor groups |
| Q43654240 | Relation of level of B-type natriuretic peptide with outcomes in patients with infective endocarditis |
| Q51767101 | Relation of osteoprotegerin to coronary calcium and aortic plaque (from the Dallas Heart Study). |
| Q37597280 | Relation of regional fat distribution to left ventricular structure and function |
| Q46943255 | Relation of troponin elevation to outcome in patients with infective endocarditis |
| Q38932720 | Relationship Between Physical Activity, Body Mass Index, and Risk of Heart Failure |
| Q53558225 | Relationship between C-reactive protein and subclinical atherosclerosis: the Dallas Heart Study. |
| Q30588473 | Relationship between perceptions about neighborhood environment and prevalent obesity: data from the Dallas Heart Study |
| Q38377195 | Relationship of Autoantibodies to MDA-LDL and ApoB-Immune Complexes to Sex, Ethnicity, Subclinical Atherosclerosis, and Cardiovascular Events |
| Q37434626 | Relationship of oxidized phospholipids on apolipoprotein B-100 particles to race/ethnicity, apolipoprotein(a) isoform size, and cardiovascular risk factors: results from the Dallas Heart Study |
| Q61634384 | Reply |
| Q87245555 | Reply: safety of same-day discharge after percutaneous coronary intervention: what is the level of evidence? |
| Q110661799 | Response by Hendren et al to Letter Regarding Article, "Association of Body Mass Index and Age With Morbidity and Mortality in Patients Hospitalized With COVID-19: Results From the American Heart Association COVID-19 Cardiovascular Disease Registry" |
| Q91225767 | Response by Jia et al to Letter Regarding Article, "High-Sensitivity Troponin I and Incident Coronary Events, Stroke, Heart Failure Hospitalization, and Mortality in the ARIC Study" |
| Q102203714 | Response by Lewis and de Lemos to Letter Regarding Article, "Racial Differences in Malignant Left Ventricular Hypertrophy and Incidence of Heart Failure: A Multicohort Study" |
| Q54100395 | Response by de Lemos et al to Letter Regarding Article "Factors Associated With Left Atrial Remodeling in the General Population". |
| Q31095242 | Revascularization Trends in Patients With Diabetes Mellitus and Multivessel Coronary Artery Disease Presenting With Non-ST Elevation Myocardial Infarction: Insights From the National Cardiovascular Data Registry Acute Coronary Treatment and Interven |
| Q55414824 | Risk Score to Predict Need for Intensive Care in Initially Hemodynamically Stable Adults With Non-ST-Segment-Elevation Myocardial Infarction. |
| Q40816866 | Risk factor burden and control at the time of admission in patients with acute myocardial infarction: Results from the NCDR. |
| Q34027392 | Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis |
| Q84098484 | Risk scores versus natriuretic peptides for identifying prevalent stage B heart failure |
| Q47631740 | Role of Hospital Volumes in Identifying Low-Performing and High-Performing Aortic and Mitral Valve Surgical Centers in the United States. |
| Q34426723 | ST segment resolution as a tool for assessing the efficacy of reperfusion therapy |
| Q73189810 | ST-segment resolution and infarct-related artery patency and flow after thrombolytic therapy. Thrombolysis in Myocardial Infarction (TIMI) 14 investigators |
| Q28198865 | Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial |
| Q44251940 | Same-day discharge after percutaneous coronary intervention: a meta-analysis |
| Q90571145 | Science in a Time of Crisis |
| Q81117695 | Screening for cardiovascular disease using B-type natriuretic peptides: detecting an imbalance of the four humours |
| Q46068885 | Screening the population for left ventricular hypertrophy and left ventricular systolic dysfunction using natriuretic peptides: results from the Dallas Heart Study |
| Q49379134 | Sedentary Behavior and Subclinical Cardiac Injury: Results From the Dallas Heart Study |
| Q86249277 | Separating the VAT from the FAT: new insights into the cardiometabolic risks of obesity |
| Q84290920 | Separating the contenders from the pretenders: competitive high-throughput biomarker screening in large population-based studies |
| Q46883862 | Serial measurement of monocyte chemoattractant protein-1 after acute coronary syndromes: results from the A to Z trial |
| Q51927734 | Sex differences in the association between leptin and CRP: results from the Dallas Heart Study. |
| Q37341817 | Sex differences in the relationship between C-reactive protein and body fat. |
| Q38762587 | Sex-Based Differences in Cardiometabolic Biomarkers |
| Q52382384 | Short-Term Global Cardiovascular Disease Risk Prediction in Older Adults. |
| Q37791189 | Should We Focus on Novel Risk Markers and Screening Tests to Better Predict and Prevent Cardiovascular Disease? |
| Q40568978 | Soluble CD40L: risk prediction after acute coronary syndromes |
| Q85635202 | Soluble ST2 is associated with all-cause and cardiovascular mortality in a population-based cohort: the Dallas Heart Study |
| Q47829267 | Soluble endothelial cell-selective adhesion molecule and incident cardiovascular events in a multiethnic population. |
| Q24193862 | Statins for acute coronary syndrome |
| Q24236697 | Statins for acute coronary syndrome |
| Q24243557 | Statins for acute coronary syndrome |
| Q38221826 | Surrogate and clinical outcomes following ischemic postconditioning during primary percutaneous coronary intervention of ST--segment elevation myocardial infarction: a meta-analysis of 15 randomized trials |
| Q91329115 | Susceptibility of Cardiac Troponin Assays to Biotin Interference |
| Q44115384 | Symmetrical dimethylarginine predicts mortality in the general population: observations from the Dallas heart study |
| Q39912878 | Systems-based improvement in door-to-balloon times at a large urban teaching hospital: a follow-up study from Parkland Health and Hospital System |
| Q22241926 | TIMI Risk Score for ST-Elevation Myocardial Infarction: A Convenient, Bedside, Clinical Score for Risk Assessment at Presentation : An Intravenous nPA for Treatment of Infarcting Myocardium Early II Trial Substudy |
| Q36279001 | Target Organ Complications and Cardiovascular Events Associated With Masked Hypertension and White-Coat Hypertension: Analysis From the Dallas Heart Study |
| Q37452299 | Target organ complications and prognostic significance of alerting reaction: analysis from the Dallas Heart Study. |
| Q92492053 | Temporal Trends in Racial Differences in 30-Day Readmission and Mortality Rates After Acute Myocardial Infarction Among Medicare Beneficiaries |
| Q28266097 | Tenecteplase and tirofiban in ST-segment elevation acute myocardial infarction: results of a randomized trial |
| Q96429892 | The American Heart Association COVID-19 CVD Registry powered by Get With The Guidelines® |
| Q31035549 | The Association of Previous Revascularization With In-Hospital Outcomes in Acute Myocardial Infarction Patients: Results From the National Cardiovascular Data Registry |
| Q92966676 | The Challenges of Observational Comparative Effectiveness Research |
| Q53395612 | The association between peptidoglycan recognition protein-1 and coronary and peripheral atherosclerosis: Observations from the Dallas Heart Study. |
| Q81909868 | The association between plasma caspase-3, atherosclerosis, and vascular function in the Dallas Heart Study |
| Q80813824 | The association of differing measures of overweight and obesity with prevalent atherosclerosis: the Dallas Heart Study |
| Q39510699 | The association of left ventricular ejection fraction with clinical outcomes after myocardial infarction: Findings from the Acute Coronary Treatment and Intervention Outcomes Network (ACTION) Registry-Get With the Guidelines (GWTG) Medicare-linked d |
| Q46720667 | The effect of a disease management algorithm and dedicated postacute coronary syndrome clinic on achievement of guideline compliance: results from the parkland acute coronary event treatment study |
| Q82429025 | The effects of rosiglitazone on myocardial triglyceride content in patients with type 2 diabetes: a randomised, placebo-controlled trial |
| Q35021842 | The incidence of kidney injury for patients treated with a high-potency versus moderate-potency statin regimen after an acute coronary syndrome |
| Q47660040 | The obesity paradox, extreme obesity, and long-term outcomes in older adults with ST-segment elevation myocardial infarction: results from the NCDR. |
| Q48766104 | The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes |
| Q44054761 | The prognostic value of serum myoglobin in patients with non-ST-segment elevation acute coronary syndromes. Results from the TIMI 11B and TACTICS-TIMI 18 studies |
| Q53144091 | The relationship between C-reactive protein and atherosclerosis differs on the basis of body mass index: the Dallas Heart Study. |
| Q44486755 | The relationship of body mass and fat distribution with incident hypertension: observations from the Dallas Heart Study |
| Q73160566 | The search for a biomarker of cardiac ischemia |
| Q79899186 | The skinny on fatty acid-binding protein |
| Q36632030 | Thiazolidinediones and risk for atherosclerosis: pleiotropic effects of PPar gamma agonism |
| Q81483527 | Thrombus precursor protein and clinical outcomes in patients with acute coronary syndromes |
| Q80189487 | Time is muscle in primary PCI: the strength of the evidence grows |
| Q51788882 | Time to Retire the BMI?: Evaluating Abdominal Adipose Tissue Imaging as Novel Cardiovascular Risk Biomarker. |
| Q33558046 | Timing of in-hospital coronary artery bypass graft surgery for non-ST-segment elevation myocardial infarction patients results from the National Cardiovascular Data Registry ACTION Registry-GWTG (Acute Coronary Treatment and Intervention Outcomes Ne |
| Q57565105 | Treatment of Hypertension in Patients With Coronary Artery Disease |
| Q57565098 | Treatment of hypertension in patients with coronary artery disease |
| Q28080534 | Treatment of hypertension in patients with coronary artery disease: a scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension |
| Q34469638 | Treatment of hypertension in patients with coronary artery disease: a scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. |
| Q92363776 | Trends in Performance and Opportunities for Improvement on a Composite Measure of Acute Myocardial Infarction Care |
| Q31151434 | Trends in U.S. Cardiovascular Care: 2016 Report From 4 ACC National Cardiovascular Data Registries |
| Q37188501 | Trends in use of anti-thrombotic agents and outcomes in patients with non-ST-segment elevation myocardial infarction (NSTEMI) managed with an invasive strategy |
| Q34397304 | Troponin T and N-terminal pro-B-type natriuretic peptide: a biomarker approach to predict heart failure risk--the atherosclerosis risk in communities study |
| Q33752845 | Troponin-positive, MB-negative patients with non-ST-elevation myocardial infarction: An undertreated but high-risk patient group: Results from the National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network-Get W |
| Q48920106 | Unexpected BNP levels in patients with advanced heart failure: a tale of caution and promise |
| Q90263165 | Unfavorable perceived neighborhood environment associates with less routine healthcare utilization: Data from the Dallas Heart Study |
| Q37836047 | Updated evidence on early statin therapy for acute coronary syndromes: meta-analysis of 18 randomized trials involving over 14,000 patients |
| Q36174003 | Urinary tract infection in patients with acute coronary syndrome: a potential systemic inflammatory connection |
| Q41507292 | Use and Outcomes of Triple Therapy Among Older Patients With Acute Myocardial Infarction and Atrial Fibrillation |
| Q92590186 | Use of Guideline-Recommended Risk Reduction Strategies Among Patients With Diabetes and Atherosclerotic Cardiovascular Disease |
| Q47876246 | Use of a highly sensitive assay for cardiac troponin T and N-terminal pro-brain natriuretic peptide to diagnose acute rejection in pediatric cardiac transplant recipients |
| Q30671378 | Use of aldosterone antagonists at discharge after myocardial infarction: results from the National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network (ACTION) Registry-Get with the Guidelines (GWTG). |
| Q48229503 | Use of natriuretic peptides in clinical decision-making for patients with non-ST-elevation acute coronary syndromes |
| Q38631705 | Utilization, Characteristics, and In-Hospital Outcomes of Coronary Artery Bypass Grafting in Patients With ST-Segment-Elevation Myocardial Infarction: Results From the National Cardiovascular Data Registry Acute Coronary Treatment and Intervention O |
| Q44950886 | Validated risk score predicts the development of congestive heart failure after presentation with unstable angina or non-ST-elevation myocardial infarction: results from OPUS-TIMI 16 and TACTICS-TIMI 18. |
| Q92705266 | Validation and implementation of the fifth-generation high sensitivity Troponin T (hs-TnT) assay at a large teaching county hospital. A laboratory-driven multi-speciality effort |
| Q101044125 | Value of Coronary Artery Calcium Scanning in Association With the Net Benefit of Aspirin in Primary Prevention of Atherosclerotic Cardiovascular Disease |
| Q87650327 | What constitutes a relevant change in high-sensitivity troponin values over serial measurement? |
Search more.